AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.15+0.00 (+0.13%)
Close on Nov 12, 2026Market cap $4.52MP/E –Yield –
AIM ImmunoTech profit margin
Profit margin (net margin) is net income as a percentage of revenue.
AIM ImmunoTech's profit margin for the twelve months ending Sep 30, 2026 was -15526.4%. For fiscal 2025 it was -15861.4%, against -10188.2% the year before. The highest annual figure on record is -1889.9% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -15861.4% | −5673.1 |
| FY2024 | Dec 31, 2024 | -10188.2% | +4149.4 |
| FY2023 | Dec 31, 2023 | -14337.6% | −546.8 |
| FY2022 | Dec 31, 2022 | -13790.8% | +377.4 |
| FY2021 | Dec 31, 2021 | -14168.1% | −5333.8 |
| FY2020 | Dec 31, 2020 | -8834.4% | −2117.2 |
| FY2019 | Dec 31, 2019 | -6717.1% | −4039.5 |
| FY2018 | Dec 31, 2018 | -2677.7% | −787.7 |
| FY2017 | Dec 31, 2017 | -1889.9% | +6264.4 |
| FY2016 | Dec 31, 2016 | -8154.3% | +3296.8 |
| FY2015 | Dec 31, 2015 | -11451.1% | −2593.3 |
| FY2014 | Dec 31, 2014 | -8857.9% | +1958.8 |
| FY2013 | Dec 31, 2013 | -10816.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -14286.4% | −1655.6 |
| Q2 FY2026 | Jun 30, 2026 | -14569.2% | −3393.2 |
| Q1 FY2026 | Mar 31, 2026 | -13740.9% | +9415.3 |
| Q4 FY2025 | Dec 31, 2025 | -19881.0% | −6621.0 |
| Q3 FY2025 | Sep 30, 2025 | -12630.8% | −2059.3 |
| Q2 FY2025 | Jun 30, 2025 | -11176.0% | −7504.0 |
| Q1 FY2025 | Mar 31, 2025 | -23156.3% | −8613.7 |
| Q4 FY2024 | Dec 31, 2024 | -13260.0% | +6087.7 |
| Q3 FY2024 | Sep 30, 2024 | -10571.4% | +6419.9 |
| Q2 FY2024 | Jun 30, 2024 | -3672.0% | +4165.5 |
| Q1 FY2024 | Mar 31, 2024 | -14542.5% | +15862.3 |
| Q4 FY2023 | Dec 31, 2023 | -19347.7% | −3177.7 |
| Q3 FY2023 | Sep 30, 2023 | -16991.3% | −5415.5 |
| Q4 FY2022 | Dec 31, 2022 | -7837.5% | +3854.5 |
| Q3 FY2022 | Sep 30, 2022 | -30404.8% | −18810.8 |
| Q2 FY2022 | Jun 30, 2022 | -16170.0% | +9377.8 |
| Q1 FY2022 | Mar 31, 2022 | -11575.8% | +1206.4 |
| Q4 FY2021 | Dec 31, 2021 | -11692.0% | −2325.3 |
| Q3 FY2021 | Sep 30, 2021 | -11593.9% | −2410.6 |
| Q2 FY2021 | Jun 30, 2021 | -25547.8% | −17122.8 |
| Q1 FY2021 | Mar 31, 2021 | -12782.1% | −4319.9 |
| Q4 FY2020 | Dec 31, 2020 | -9366.7% | −7240.7 |
| Q3 FY2020 | Sep 30, 2020 | -9183.3% | −4350.5 |
| Q2 FY2020 | Jun 30, 2020 | -8425.0% | −1404.3 |
| Q1 FY2020 | Mar 31, 2020 | -8462.2% | −7786.8 |
| Q4 FY2019 | Dec 31, 2019 | -2126.0% | +5974.0 |
| Q3 FY2019 | Sep 30, 2019 | -4832.8% | +2485.4 |
| Q2 FY2019 | Jun 30, 2019 | -7020.7% | −2176.0 |
| Q4 FY2018 | Dec 31, 2018 | -675.4% | +3310.6 |
| Q3 FY2018 | Sep 30, 2018 | -8100.0% | −6708.9 |
| Q2 FY2018 | Jun 30, 2018 | -7318.2% | −6288.6 |
| Q1 FY2018 | Mar 31, 2018 | -4844.6% | −1486.3 |
| Q4 FY2017 | Dec 31, 2017 | -3986.0% | +3345.3 |
| Q3 FY2017 | Sep 30, 2017 | -1391.1% | +11618.0 |
| Q2 FY2017 | Jun 30, 2017 | -1029.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -3358.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -7331.3% | – |
| Q3 FY2016 | Sep 30, 2016 | -13009.1% | – |
See a number that looks wrong?